Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Chofflon

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 7, 2005
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?Michel Chofflon
Revue Medicale De La Suisse Romande|April 21, 2004
[Multiple sclerosis: current therapeutic strategies]Michel Chofflon
Revue Medicale Suisse|January 22, 2010
[Inflammatory neuropathies and multineuritis]Thierry Kuntzer, Michel Chofflon
Revue Medicale De La Suisse Romande|April 21, 2004
[Various infective diseases of the nervous system]Natalia Vokatch, Michel Chofflon
Revue Medicale Suisse|July 25, 2008
[The painful multiple sclerosis]Michel Chofflon, Patrice H Lalive
Clinical Neurology and Neurosurgery|July 20, 2002
Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosisMichel Chofflon, Ali Frederic Ben-Amor
Experimental Dermatology|October 20, 2015
One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1Kseniia Künzli, Bertrand Favre, Michel Chofflon, et al.
Behavioral Neuroscience|December 21, 2002
TNF-alpha and psychologically stressful events in healthy subjects: potential relevance for multiple sclerosis relapsePatrice H Lalive, Pierre R Burkhard, Michel Chofflon
BMJ Case Reports|August 30, 2013
Illustrating the relevance of updated diagnostic criteria for sporadic Creutzfeldt-Jakob disease: a teaching neurocaseJoseph Kamtchum Tatuene, Maria Isabel Vargas, Karim Burkhardt, et al.
European Neurology|February 8, 2014
Dual-task assessment in natalizumab-treated multiple sclerosis patientsGilles Allali, Magali Laidet, Frédéric Assal, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 7, 2005
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?Michel Chofflon
Revue Medicale De La Suisse Romande|April 21, 2004
[Multiple sclerosis: current therapeutic strategies]Michel Chofflon
Revue Medicale Suisse|January 22, 2010
[Inflammatory neuropathies and multineuritis]Thierry Kuntzer, Michel Chofflon
Revue Medicale De La Suisse Romande|April 21, 2004
[Various infective diseases of the nervous system]Natalia Vokatch, Michel Chofflon
Revue Medicale Suisse|July 25, 2008
[The painful multiple sclerosis]Michel Chofflon, Patrice H Lalive
Clinical Neurology and Neurosurgery|July 20, 2002
Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosisMichel Chofflon, Ali Frederic Ben-Amor
Experimental Dermatology|October 20, 2015
One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1Kseniia Künzli, Bertrand Favre, Michel Chofflon, et al.
Behavioral Neuroscience|December 21, 2002
TNF-alpha and psychologically stressful events in healthy subjects: potential relevance for multiple sclerosis relapsePatrice H Lalive, Pierre R Burkhard, Michel Chofflon
BMJ Case Reports|August 30, 2013
Illustrating the relevance of updated diagnostic criteria for sporadic Creutzfeldt-Jakob disease: a teaching neurocaseJoseph Kamtchum Tatuene, Maria Isabel Vargas, Karim Burkhardt, et al.
European Neurology|February 8, 2014
Dual-task assessment in natalizumab-treated multiple sclerosis patientsGilles Allali, Magali Laidet, Frédéric Assal, et al.
Pageof 2